Printer Friendly

Cisplatin may be effective option for patients who react to carboplatin.

HOT SPRINGS, VA. -- Patients with ovarian cancer who have a hypersensitivity reaction to carboplatin can be successfully treated with cisplatin without a lengthy desensitization procedure, Dr. Megan Callahan said at the annual meeting of the South Atlantic Association of Obstetricians and Gynecologists.

She presented a review of 24 women with ovarian cancer who received cisplatin after an allergic reaction to carboplatin. It is the largest case series to date.

Carboplatin hypersensitivity is correlated with the number of treatment cycles experienced, said Dr. Callahan of the University of Virginia, Charlottesville. "The cumulative risk increases from 0.92% for less than five cycles to 6.5% for six cycles, and up to 19% for eight cycles," she said. Her patients' reactions occurred at a median of 10 cycles. None of the reactions was life threatening.

All of the patients were rechallenged with cisplatin in a subsequent treatment cycle. The drug was given at a standard infusion rate over 1.5 hours. None of the patients received desensitization with steroids or antihistamines.

Most (18) were able to tolerate the full number of cisplatin treatment cycles without a hypersensitivity reaction. Only one of the six who reacted to cisplatin did so in the first cycle. The rest were able to tolerate 1-6 cycles before having a reaction. All of the cisplatin reactions were managed conservatively on an outpatient basis.

Dr. Callahan's 24 patients bring the total reported in the literature to 57. Among these patients, only seven had cisplatin reactions, and one died. "This results in an 86% success rate for cisplatin rechallenge."

She added that she has not been able to identify any predisposing factors that might predict which patients would react to either drug. "We looked at past medical history, reported allergies, and concurrent medications, and we couldn't identify anything." The severity of the initial carboplatin reaction also did not help predict which patients would later experience a cisplatin reaction.

COPYRIGHT 2007 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Women's Health
Author:Sullivan, Michele G.
Publication:Family Practice News
Date:Apr 1, 2007
Words:318
Previous Article:Ovarian cancer blood test accuracy rates improved.
Next Article:Cocaine use by pregnant women.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters